Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.
Fiscal year to December 2025, from the company's annual filing with the SEC.
| Salesyearly sales | $2.3B |
| Sales growthchange from the year before | +35.9% |
| Operating marginshare of sales left after running the business | -13.4% |
| Net marginshare of sales kept as profit | -9.0% |
| Free-cash-flow marginspare cash generated per $100 of sales | 4.7% |
| Return on invested capitalprofit made on each $100 put into the business | -14.3% |
| Return on equityprofit vs. shareholders' accounting value | -12.2% |
| Interest coverhow many times profit covers interest payments | -76.2x |
| Change in share countnegative = the company is buying back its shares | +9.6% |
7 insiders sold $7.2M (all under pre-arranged plans) on the open market.
| Brophy Michael BurkesChief Financial Officer | Sold (plan)Aug 4 | 478 shat $274.22 · $131K |
| Rabinowitz MatthewExecutive Chairman · Director | Sold (plan)Aug 3 | 731 shat $267.99 · $196K |
| Sheena JonathanDirector | Sold (plan)Aug 3 | 109 shat $267.99 · $29K |
From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.
Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy